Head-To-Head Contrast: Creative Medical Technology (NASDAQ:CELZ) vs. Prima BioMed (NASDAQ:IMMP)

Creative Medical Technology (NASDAQ:CELZ) and Prima BioMed (NASDAQ:IMMP) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, risk, valuation, profitability, dividends, analyst recommendations and institutional ownership.

Valuation and Earnings

This table compares Creative Medical Technology and Prima BioMed”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Creative Medical Technology	$10,000.00	913.90	-$5.99 million	($2.59)	-0.95
Prima BioMed	$6.69 million	12.86	-$39.78 million	N/A	N/A

Creative Medical Technology has higher earnings, but lower revenue than Prima BioMed.

Profitability

This table compares Creative Medical Technology and Prima BioMed’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Creative Medical Technology	N/A	-85.62%	-82.36%
Prima BioMed	N/A	N/A	N/A

Insider & Institutional Ownership

1.4% of Creative Medical Technology shares are owned by institutional investors. Comparatively, 2.3% of Prima BioMed shares are owned by institutional investors. 1.7% of Creative Medical Technology shares are owned by company insiders. Comparatively, 3.1% of Prima BioMed shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Risk & Volatility

Creative Medical Technology has a beta of 1.94, suggesting that its stock price is 94% more volatile than the S&P 500. Comparatively, Prima BioMed has a beta of 2.16, suggesting that its stock price is 116% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Creative Medical Technology and Prima BioMed, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Creative Medical Technology	1	1	0	0	1.50
Prima BioMed	1	3	0	0	1.75

Prima BioMed has a consensus price target of $5.50, suggesting a potential upside of 841.78%. Given Prima BioMed’s stronger consensus rating and higher probable upside, analysts clearly believe Prima BioMed is more favorable than Creative Medical Technology.

Summary

Prima BioMed beats Creative Medical Technology on 8 of the 10 factors compared between the two stocks.

About Creative Medical Technology

Creative Medical Technology Holdings, Inc., a commercial stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; and StemSpine, a regenerative stem cell procedure to treat degenerative disc disease. It also develops ImmCelz, an immunotherapy platform for multiple diseases; OvaStem for treatment of female infertility; CELZ-201 to treat Type 1 diabetes; AlloStemSpine for the treatment of chronic lower back pain; and Alova to treat infertility as a result of premature ovarian failure. In addition, the company develops products and services for various indications, including preventing the rejection of transplanted organs, kidney failure, liver failure, heart attack, and Parkinson's disease. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.

About Prima BioMed

Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system. Its LAG-3 immunotherapies are designed to harness and strengthen the power of patients' immune systems to fight cancer and autoimmune disease. Its lead product candidate is eftilagimod alpha (efti or IMP321) for the treatment of different types of cancers. The trials that efi is being evaluated in include TACTI-002, a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC); TACTI-003, a Phase IIb clinical trial to treat HNSCC; and INSIGHT-003, a Phase I clinical trial for the treatment of NSCLC, as well as INSIGHT-005, a Phase I/IIa clinical trial to treat solid tumors. In addition, it offers IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. The company has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is headquartered in Sydney, Australia.